Treatment News : Vertex Hep C Protease Inhibitor Receives Approval Recommendation

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 28, 2011

Vertex Hep C Protease Inhibitor Receives Approval Recommendation

The Antiviral Drugs Advisory Committee (ADAC) of the U.S. Food and Drug Administration (FDA) voted 18 to 0 to recommend approval of telaprevir, Vertex Pharmaceuticals' experimental hepatitis C virus (HCV) protease inhibitor. The panel of independent experts met Thursday, April 28, to review the company's New Drug Application requesting approval for the drug.

The expert panel’s nod of approval follows a similar unamimous recommendation for Merck’s HCV protease inhibitor Victrelis (boceprevir) on Wednesday, April 27. 

Telaprevir, with the ADAC panel’s recommendation, now goes to the FDA for final consideration as a treatment for HCV genotype 1 infection in combination with current standard therapy, notably pegylated interferon and ribavirin. The agency will consider the drug's established safety and efficacy for those who have not yet been treated for HCV and for those who have been treated previously but were not cured with currently available medications.

The advisory committee panel reviewed the results from three pivotal clinical trials—ADVANCE, ILLUMINATE and REALIZE—which evaluated telaprevir in combination with pegylated interferon and ribavirin in people who were not treated previously and in the three major subgroups of patients who did not respond favorably to earlier treatment: Relapsers, partial responders and null responders.

Vertex anticipates a decision for the FDA by May 23.

Search: Vertex, telaprevir, FDA, ADAC, approval, recommendation, ADVANCE, ILLUMINATE, REALIZE


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    chipper52
    Palm Springs
    California


    RyGuy00
    New York
    New York


    TaintedloveDC
    Washington
    DC


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.